ArticleFood science & nutrition2026
Mechanistic Study of Schisandrin B in Alleviating Anxiety-Like Behaviors in Rats via Enhancement of Hippocampal Synaptic Plasticity and Restoration of the Intestinal Barrier.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focused on examining the anxiolytic effects of Schisandrin B (SchB) in rats exhibiting anxiety-like behaviors and investigating the mechanisms involved. Behavioral assessments were conducted using the elevated plus-maze test and the open field test. The results showed that Schisandrin B at a dose of 10 mg/kg significantly alleviated anxiety-like behaviors in rats, with an efficacy comparable to that of the positive control drug diazepam. Mechanistic studies indicate that, at the central level, Schisandrin B effectively maintains the homeostasis of the glutamatergic system in the hippocampus and the HPA axis. Specifically, Schisandrin B downregulates the stress-induced overexpression of ionotropic glutamate receptor subunits at both the mRNA and protein levels, including NMDAR subtypes (GluN1A, GluN2A, and GluN2B) and AMPAR subtypes (GluA1 and GluA2), thereby restoring the glutamate/γ-aminobutyric acid (Glu/GABA) ratio to physiological levels. In addition, Schisandrin B suppresses the hyperactivation of the HPA axis by reducing the secretion of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and corticosterone (CORT). Meanwhile, it ameliorates neuronal and synaptic ultrastructural damage in the hippocampus and upregulates the expression of synaptic plasticity-related proteins, SYP and PSD-95, thereby improving synaptic transmission and function. At the peripheral intestinal level, Schisandrin B alleviated colon shortening in anxiety-model rats and reduced fecal pH, thereby improving intestinal environmental homeostasis. Schisandrin B also promoted the upregulation of tight junction proteins (ZO-1, Occludin, and Claudin-1) in the colonic tissues, contributing to the restoration of colonic mucosal integrity, attenuation of inflammatory infiltration, and reinforcement of intestinal barrier function. Collectively, Schisandrin B exerts systemic anxiolytic effects by centrally regulating hippocampal glutamatergic neurotransmission, HPA axis activity, and synaptic plasticity, while simultaneously repairing peripheral intestinal barrier dysfunction. These results indicate the potential of Schisandrin B as a therapeutic candidate for anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.